|
|
|
| Impact of Pharmacovigilance Based on PCNE Classification System on Treatment Outcomes, DRPs in Patients with Diabetic Nephropathy |
| ZHANG Yan, LI Man, LU Xinyan |
| Department of Pharmacy, Qingpu Branch, Zhongshan Hospital Affiliated to Fudan University, Shanghai 201700, China |
|
|
|
|
Abstract Objective To observe the effects of pharmaceutical care based on the Pharmaceutical Care Network Europe (PCNE) classification system on the treatment outcomes and drug-related problems (DRPs) of patients with diabetic nephropathy (DN). Methods A total of 120 patients with DN admitted to the hospital from May 2021 to May 2022 were selected and divided into control group and intervention group with 60 cases each by random serial numbers generated by Excel. The control group received medication according to the doctor’s orders, without pharmaceutical care, and the intervention group received pharmaceutical care through the PCNE system. The clinical indicators and medication adherence were compared. The treatment outcomes and DRPs of the two groups were compared. Results After the intervention, the fasting blood glucose (FBG), systolic blood pressure, diastolic blood pressure, triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL-C), serum uric acid (SUA), and 24 h urine protein quantification of the two groups were decreased, and which of the intervention group were lower than those of the control group. The high-density lipoprotein (HDL-C) and Morisky Medication Adherence Scale (MMAS-8) scores of the two groups were increased, and which of the intervention group were higher than those of the control group. The distribution of treatment outcome levels and the total effective rate of the intervention group were higher than those of the control group, but the incidence of DRPs was lower. Conclusion Pharmaceutical care based on the PCNE classification system can improve the treatment outcomes of DN patients, increase their medication adherence, and reduce DRPs.
|
|
Received: 11 May 2024
|
|
|
|
[1] TUTTLE KR, JONES CR, DARATHA KB, et al.Incidence of chronic kidney disease among adults with diabetes, 2015-2020[J]. N Engl J Med, 2022, 387(15): 1430-1431.
[2] HOY WE, WANG Z, ZHANG J, et al.Chronic kidney disease in public renal practices in Queensland, Australia, 2011-2018[J]. Nephrology (Carlton), 2022, 27(12): 934-944.
[3] MASLUB MG, RADWAN MA, MIKHAIL MS, et al.Assessment of the latest prescribed drug-related problems[J]. Eur Rev Med Pharmacol Sci, 2022, 26(7): 2373-2387.
[4] WANG Y, ZHU J, SHAN L, et al.Drug-related problems in bariatric surgery: a retrospective study[J]. Obes Surg, 2022, 32(12): 3961-3972.
[5] TIAN L, WU J, QI Z, et al.Drug-related problems among community-dwelling elderly with ischemic stroke in China[J]. Adv Clin Exp Med, 2023, 32(4): 423-432.
[6] SATRIA MA, ANDRAJATI R, SUPARDI S.The translation process of pharmaceutical care network europe v9.00 to bahasa indonesia: An instrument to detect drug-related problem[J]. Malays J Med Sci, 2022, 29(3): 133-144.
[7] NGUYEN KT, LE VTT, NGUYEN TH, et al.Effect of pharmacist-led interventions on physicians' prescribing for pediatric outpatients[J]. Healthcare (Basel), 2022, 10(4): 751.
[8] AGNOL RD, DOS SANTOS MT, MICHALOWSKI MB, et al.Pharmacists' interventions on 2 years of drug monitoring in an oncology pediatric inpatient ward[J]. J Oncol Pharm Pract, 2022, 28(8): 1754-1762.
[9] LIU H, ZHONG Y, ZENG Z, et al.Drug-related problems in hospitalised Parkinson's disease patients in China[J]. Eur J Hosp Pharm, 2022, 29(6): 308-312.
[10] AYHAN YE, KARAKURT S, SANCAR M.The effect of the clinical pharmacist in minimizing drug-related problems and related costs in the intensive care unit in Turkey: A non-randomized controlled study[J]. J Clin Pharm Ther, 2022, 47(11): 1867-1874.
[11] HATA S, USHIGOME E, HOSOMI Y, et al.Impact of continued high blood pressure on the progression of diabetic nephropathy after 10 years: KAMOGAWA-HBP study[J]. Hypertens Res, 2023, 46(3): 565-574.
[12] 胡煜琳, 杜晓刚. 血脂水平及血脂异常不同临床分类与糖尿病肾病的相关性及预测价值研究[J]. 四川大学学报(医学版), 2023, 54(5): 1013-1018.
[13] ZHU L, SUN J, WANG X, et al.Elevated serum uric acid is not an independent risk factor for the occurrence of Type 2 diabetic kidney disease in Chinese populations[J]. Medicine (Baltimore), 2022, 101(50): e32128.
[14] BALAR S, BEKE N, PATKI D, et al.The correlation of urine protein/osmolality and protein/creatinine ratio as predictor of 24-hour urinary protein excretion[J]. J Assoc Physicians India, 2023, 71(5): 11-12.
[15] 中华医学会糖尿病学分会微血管并发症学组. 中国糖尿病肾脏病防治指南 (2021年版)[J]. 中华糖尿病杂志, 2021, 13(8): 762-784.
[16] LI-WAN-PO A, PETERSON GM. Drug compliance and the Morisky Adherence Scale: An expression of concern and a warning[J]. J Clin Pharm Ther, 2021, 46(1): 1-3.
[17] 上海市肾内科临床质量控制中心专家组. 慢性肾脏病早期筛查, 诊断及防治指南 (2022年版)[J]. 中华肾脏病杂志, 2022, 38(5): 453-464.
[18] AGNOL RD, DOS SANTOS MT, MICHALOWSKI MB, et al.Pharmacists' interventions on 2 years of drug monitoring in an oncology pediatric inpatient ward[J]. J Oncol Pharm Pract, 2022, 28(8): 1754-1762.
[19] TIAN L, WU J, QI Z, et al.Drug-related problems among community-dwelling elderly with ischemic stroke in China[J]. Adv Clin Exp Med, 2023, 32(4): 423-432.
[20] ÜNDER D, ENVER C, DEMIRCI MY, et al.Clinical pharmacist-led medication review in hospitalized confirmed or probable patients with COVID-19 during the first wave of COVID-19 pandemic[J]. Turk J Pharm Sci, 2024, 21(2): 152-158.
[21] SATIR AN, PFIFFNER M, MEIER CR, et al.Prescribing patterns in pediatric general wards and their association with prescribing errors: A retrospective observational study[J]. Drugs Real World Outcomes, 2023, 10(4): 619-629.
[22] 毕莹, 刘林林, 陈琳, 等. 药师运用欧洲药学监护联盟分类系统参与髋部骨折患者围术期药物管理的意义[J]. 药品评价, 2023, 20(1): 5-9.
[23] 符方方, 周国波, 林聪茹, 等. 临床药师开展心血管内科入院患者药物重整的实践[J]. 中国药房, 2022, 33(10): 1263-1268.
[24] 储菲, 姚扬, 杨秀木, 等. 基于PCNE分类方法对社区2型糖尿病患者实施个体化药学服务的效果[J]. 南昌大学学报 (医学版), 2022, 62(2): 60-64+103.
[25] 韩亚珠, 张红煜, 杜亚杰, 等.2型糖尿病合并慢性肾脏病患者实施药学监护的前瞻性队列研究[J]. 中国医院药学杂志, 2023, 43(13): 1430-1434. |
|
|
|
2024, Vol. 21 
